[Naiz (nimesulid) in combined treatment of patients with chronic non-bacterial prostatitis with chronic pelvic pain syndrome].
Naiz (nimesulid) was given to 46 patients (age 24-52 years) with chronic abacterial prostatitis suffering from chronic pelvic pain syndrome (CPPS) which appeared from 20 to 3 years before the treatment. Microscopy of prostatic secretion showed normal count of leukocytes. Transrectal ultrasound investigation with dopplerography has found normal echostructure of the prostate but blood flow parameters were subnormal. Naiz was given in a dose 100 mg (1 tablet) twice a day for 15-20 days. The treatment relieved pain in 68-87% patients (mean 77.5%). The control ultrasound investigation detected much better circulation. Quality of life improved significantly. Side effects were mild. The effect persisted for 3 months of the follow-up. Thus, the addition of such nonsteroid antiinflammatory drug as naiz (nimesulid) to treatment of patients with chronic abacterial prostatitis is justified. The drug improves quality of life, induces side effects rarely and can be used for a long time with a persistent efficacy.
Neĭmark
A I
AI
Iakovets
Ia V
IaV
Aliev
R T
RT
D000328:Adult; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D017699:Pelvic Pain / Q000150:complications*; D011467:Prostate / Q000000981:diagnostic imaging; D011472:Prostatitis / Q000150:complications* / Q000188:drug therapy*; D011788:Quality of Life; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013577:Syndrome; D016896:Treatment Outcome; D014463:Ultrasonography
D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013449:Sulfonamides; C012655:nimesulide